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To assess bone mineral density (BMD) in girls with Turner’s
syndrome before and during long-term treatment with GH, longitudinal
measurements using phalangeal radiographic absorptiometry were per-
formed in 68 girls with Turner’s syndrome. These previously untreated
girls, age 2–11 y, participating in a randomized, dose-response trial,
were randomly assigned to one of three GH dosage groups: group A, 4
IU/m2/d (0.045 mg/kg/d); group B, first year 4 IU/m2/d, thereafter 6
IU/m2/d (0.0675 mg/kg/d); or group C, first year 4 IU/m2/d, second
year 6 IU/m2/d, thereafter 8 IU/m2/d (0.090 mg/kg/d). In the first 4 y
of GH treatment, no estrogens for pubertal induction were prescribed to
the girls. Thereafter, girls started with 17-estradiol (5 g/kg body
weight/d, orally) when they had reached the age of 12 y. BMD results
were adjusted for bone age and sex, and expressed as SD scores using
reference values of healthy Dutch girls. At baseline, almost every
individual BMD value of bone consisting predominantly of cortical
bone, as well as that of bone consisting predominantly of trabecular
bone, was within the normal range of healthy girls and the SD scores
were not significantly different from zero [mean (SE) 0.38 (0.22) and
0.04 (0.13)]. During 7 y of GH treatment, BMD SD scores showed
a significant increase to values significantly higher than zero [mean (SE)
0.87 (0.15) and 0.95 (0.14)]. The increment in BMD SD score of bone
consisting predominantly of cortical bone was significantly higher in
group C compared with that of the other two GH dosage groups. The
pretreatment bone age was significantly negatively related to the incre-
ment in BMD SD score. We found no significant influence of sponta-
neous puberty or the use of low-dose estrogens in the last 3 y of the
study period on the increment in BMD SD score during 7 y of GH
treatment. In conclusion, most untreated young girls with Turner’s
syndrome have a normal volumetric BMD. During 7 y of GH treatment
with 4, 6, or 8 IU/m2/d, the BMD SD score increased significantly.
(Pediatr Res 50: 417–422, 2001)
Abbreviations:
TS, Turner’s syndrome
BMD, bone mineral density
RA, radiographic absorptiometry
DXA, dual energy x-ray absorptiometry
PA, posteroanteriorly
LAT, lateral
ROI, region of interest
BMD50%, bone mineral density of that part of the phalanx
consisting predominantly of cortical bone (approximately 80%)
BMD25%, bone mineral density of that part of the phalanx
consisting predominantly of trabecular bone (approximately 60%)
Short adult stature and ovarian failure are the main features
in TS (1, 2). Although girls with TS are not GH-deficient (3),
many patients now receive GH treatment to increase adult
height. As most girls fail to initiate or progress through pu-
berty, estrogen replacement is required. Our previous study
showed that starting GH treatment at a relatively young age
and beginning low-dose estrogen therapy from the age of 12 y
results in a normalization of height in most girls and pubertal
development in conformity with their healthy peers (4).
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Despite limited reports of a greater number of fractures
during childhood (5) or adulthood (6, 7), osteoporosis histori-
cally has been described as a feature in TS, because of the
frequent observation of radiographic osteopenia and the coarse
trabecular pattern of the carpal bones on radiographs (8).
Because skeletal anomalies are common in females with TS,
there has been speculation that an intrinsic bone defect as well
as estrogen deficiency may explain these findings (9, 10).
Although more refined methods such as single- and dual-
photon absorptiometry and DXA have led to improved insights
into BMD status in TS, these projection methods report areal
and not true volumetric BMD, resulting in an underestimation
of the true BMD in subjects with short stature (11). Thus, it
would be preferable to measure the actual BMD, e.g. by means
of quantitative computed tomography (QCT). However, the
radiation dose using QCT is far higher than that given using
DXA. In addition, QCT is expensive and more difficult to use
in pediatric practice. In contrast, phalangeal RA determines the
BMD from a radiograph of the hand, which is already often
made for the assessment of bone age (12, 13). Several studies
in adults have shown that the RA method, using an aluminum
wedge in the field of view to correct for differences in exposure
and processing variables, is as good in predicting fracture risk
as DXA (14–16).
To assess the volumetric BMD in young girls with TS before
and during long-term treatment with recombinant human GH,
longitudinal measurements using phalangeal radiographic ab-
sorptiometry were performed in 68 girls with TS, participating
in a randomized, dose-response trial. The effect on height was
described earlier (4). We now report the results of the BMD
data over 7 y among three GH dosage groups.
METHODS
Patients and study design. Sixty-eight previously untreated
girls with TS were enrolled in a multicenter GH dose-response
study in the Netherlands. The diagnosis was confirmed by
lymphocyte chromosomal analysis. Inclusion criteria were
chronological age between 2 and 11 y, height below the 50th
percentile for healthy Dutch girls (17), and normal thyroid
function. Exclusion criteria were associated endocrine and/or
metabolic disorders, growth failure caused by other disorders
or emotional deprivation, hydrocephalus, previous use of drugs
that could interfere with GH treatment, and spontaneous pu-
berty (18). Written informed consent was obtained from the
girls and their parents or custodians. The study protocol was
approved by the ethics committee of each participating center.
After stratification for chronological age and height SD
score for chronological age, girls were randomly assigned to
the following groups: group A (n  23), receiving 4 IU/m2/d
(equivalent to 0.045 mg/kg/d); group B (n  23) receiving 4
IU/m2/d in the first year, followed by 6 IU/m2/d (0.0675
mg/kg/d); or group C (n  22) receiving 4 IU/m2/d in the first
yearr, 6 IU/m2/d in the second year, and thereafter 8 IU/m2/d
(0.090 mg/kg/d).
Recombinant human GH (Norditropin, Novo Nordisk A/S,
Bagsværd, Denmark) was given s.c. once daily at bedtime
using a pen injection system. Every 3 mo, the total GH dose
was adjusted to the calculated body surface. According to the
study protocol, treatment was stopped when subjects had
grown 1 cm over 6 mo. However, when girls were satisfied
with their achieved height, they elected to stop GH treatment
before study criteria for the termination of treatment had been
reached. In the first 4 y of GH treatment, no estrogens for
pubertal induction were prescribed to the girls. After 4 y of GH
treatment, estrogen therapy was started in the girls who were
older than 12.0 y of age; the younger girls started estrogen
therapy at a yearly visit after reaching the age of 12 y. Five
micrograms 17-estradiol/kg body weight/d, orally, were
given in the first 2 y, 7.5 g/kg/d in the third year, and 10
g/kg/d thereafter. Cyclic progestogen therapy (Duphaston,
Solvay Pharmaceuticals, Brussels, Belgium, 5 mg/d in the first
14 d of the month) was added after 2 y of estrogen therapy. If
puberty had developed spontaneously (Tanner breast stage2)
during the study period and before start of estrogens, no
estrogens were given.
Before the start of treatment (baseline) and subsequently
every 3 mo, all girls were seen at their local hospital for
measurements of height. Height was expressed as SD score
using references of healthy Dutch girls (17). Body surface was
calculated using the following formula: body surface area 
weight0.425  height0.725  0.007184 (19). Pubertal stages
were assessed according to the method of Tanner (18). Before
the start of the GH treatment (baseline), and subsequently once
a year, standardized radiographs of the left hand were taken.
Bone age was determined by two trained observers according
to the Greulich and Pyle method (20).
Radiographic absorptiometry. The standardized radio-
graphs of the left hand (PA) and the left index finger (LAT)
were taken, on a single film using a dedicated cassette (Imation
GTU film, -II Trimax intensifying screens, small 0.6-mm
focus, film focus distance 1.5 m, 45 kV, 16 mAs, Ination
International, Amsterdam, The Netherlands). Using these two
projections, it is possible to adjust for soft tissue surrounding
the middle phalanx and to assess the volume of this phalanx.
Consequently, the BMD as a “true” volumetric density can be
determined. With this technique, two measurement sites
(ROIs) are used, the first ROI is at the midpoint of the line
between the distal and proximal edge of the phalanx
(BMD50%), consisting predominantly of cortical bone (approx-
imately 80%); the second ROI is located at the proximal
quarter-point of this line (BMD25%), consisting predominantly
of trabecular bone (approximately 60%) (21). This technique
has a short-term in vivo coefficient of variance of 1%, being
slightly better than precision figures for the other RA tech-
niques (14, 22).
For the application of this technique, two identical linear
aluminum wedges were placed within the field of view of each
exposure, i.e. one for the hand (PA) and one for the index
finger (LAT), all x-rays were obtained in a strict, standardized
fashion. Interactive software developed in-house was used to
analyze all films, using a personal computer equipped with a
modular frame grabber in combination with a charge coupled
device (CCD) camera (SWK-31, DIFA Measuring Systems
BV, Breda, The Netherlands, pixel size 37.5  37.5 m)).
Analysis, performed by one operator (A.A.), consisted of several
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steps. First, the system was calibrated on a daily basis by scanning
a standard radiograph containing an image of the aluminum
wedge, to correct for influences of variances in the transmitted
light intensity. The second step involved scanning of the alumi-
num wedges (thickness 0–12 mm), to calibrate the intensity
values in the image. Then, the predefined ROIs were semiauto-
matically scanned to determine the distal and proximal edge of the
second phalanx on the digitised x-ray image. The software then
automatically determined the length and the outer contours of the
phalanx and defined the two ROIs being 3-mm wide areas. These
ROIs were placed on both the PA and LAT films. The software
combined a volumetric BMD relative to the aluminum wedge.
Because chronological age may not be indicative of biologic
development, especially in children whose disorder affects
bone maturation, all measured values of BMD50% and of
BMD25% were adjusted for bone age (20), and expressed as SD
scores (SDS) using reference values of healthy Dutch girls.
These reference values were previously described using a
piece-wise linear regression analysis (“broken stick” tech-
nique). Reference values were only available for girls with a
bone age 5.5 y (13).
Statistical analysis. Results are expressed as mean and SD
or SE, unless indicated otherwise. Differences between zero
and the mean SDS at baseline or after 7 y were tested by
one-sample t tests. Because reference data were only available
for girls with a bone age5.5 y, it was not possible to calculate
SDS of the youngest girls at baseline and in the first years of
GH treatment, resulting in missing data. In addition, a number
of girls discontinued GH treatment within the 7-y study period
because of reaching adult height, causing missing values.
Moreover, during the 7-y study period, for practical and tech-
nical reasons we could no longer obtain standardized x-rays in
a few centers. To estimate and test the effect of time, GH dose
and other variables on the changes of BMD50% SDS and
BMD25% SDS during the 7-y study period, we used repeated
measurement analysis of variance (RMANOVA) methods that
used all available data (SAS Proc Mixed, SAS Institute, Cary,
NC, U.S.A.). In these models, the yearly increase in BMD50%
SDS and BMD25% SDS was the dependent variable. To inves-
tigate the differences between the three treatment groups, the
GH dose was entered as a time-dependent categorical indepen-
dent variable. To test the effect of pretreatment bone age on the
changes in BMD50% SDS and BMD25% SDS, pretreatment
bone age was added to the model. To assess the influence of
spontaneous puberty and the influence of the use of estrogens
on the changes in BMD50% SDS and BMD25% SDS, these
factors were entered as time-dependent covariates in the
RMANOVA model. To investigate the association between the
yearly increase in BMD50% SDS and BMD25% SDS with the
yearly increase in height SDS, the latter was entered as a
time-dependent covariate in the model as well. A p value
0.05 was considered significant.
RESULTS
Three girls, one in each GH dosage group, dropped out of
the study long before reaching adult height mainly because of
noncompliance. In all three cases no problems with BMD were
involved in the decision to discontinue the treatment. Data of
these three girls were not used for the analysis of long-term GH
treatment.
Table 1 lists the baseline clinical data of the remaining 65
girls. The three groups had similar initial characteristics. After
7 y of GH treatment, two girls in group A, six girls in group B,
and four girls in group C had discontinued GH treatment
because of reaching adult height or satisfaction with height
achieved. For these girls, only data of the period during GH
treatment were available for the 7-y analysis. In addition, in 14
girls (n  4 in group A, n  5 in group B, and n  5 in group
C) there were missing values in the 7-y longitudinal data,
because of the inability to obtain standardized x-rays in a few
centers.
After the first 4 y of GH treatment, 35 of the 65 girls started
with estrogen therapy during the subsequent 3 y, whereas 5
girls did not receive estrogens because of spontaneous puberty.
Twenty-five girls were prepubertal during the entire study
period and had not started estrogen therapy because they were
younger than 12 y of age.
Figure 1 shows the individual values of BMD50% and
BMD25%, respectively, before and after 7 y of GH treatment.
At baseline, in 30 of the 65 girls, bone age was too low to
compare with reference values. Most baseline BMD50% and
BMD25% values of the remaining 35 girls were within the
normal range and rather well distributed around the mean of
healthy girls. Mean (SE) BMD50% and BMD25% SDS were
0.38 (0.22) and 0.04 (0.13), respectively, being not signifi-
cantly different from zero. After 7 y of GH treatment, BMD
data of 39 girls (n  16 in group A, n  11 in group B, and n
 12 in group C) were available. None of the BMD50% and
BMD25% values after 7 y were below 2 SD, and most values
were higher than the mean of healthy girls. The mean SDS of
the BMD50%, as well as that of the BMD25% was significantly
higher than zero [0.87 (0.15) and 0.95 (0.14), respectively, p
0.001].
Table 2 shows the number of girls per year of whom SDS
were available as well as the mean (SE) BMD SDS of these
girls per year. All available data of the 65 girls were used in the
repeated measurement analysis model to calculate the change
in BMD SDS during the 7 y of GH treatment. During 7 y of
GH treatment, the mean (SE) SDS of the BMD50%, as well as
that of the BMD25% had increased significantly compared with
baseline values 0.53 (0.16) (p  0.001) and 1.08 (0.15) (p 
0.001), respectively. The increment in BMD50% SDS was
Table 1. Mean (SD) baseline data for each treatment group.
Karyotype (45, X; other) is expressed in number (percentage) of
patients
Group A Group B Group C
Number of girls 22 22 21
Chronological age 6.1 (2.1) 6.7 (2.4) 6.5 (2.4)
Bone age (GP)† 5.0 (2.1) 5.5 (2.2) 5.5 (2.3)
Height SD score* 2.7 (0.9) 2.4 (1.0) 2.6 (1.0)
Karyotype: 45, X 18 (82%) 21 (96%) 16 (76%)
Karyotype: other 4 (18%) 1 (4%) 5 (24%)
* References healthy Dutch girls.
† Bone age according to the Greulich and Pyle method.
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significantly higher in group C (0.82) compared with group A
(0.45) and group B (0.04) (p  0.025), without significant
differences between groups A and B. No significant differences
in the 7-y increment in BMD25% SDS were found between the
GH dosage groups (1.04 in group A, 0.99 in group B, and 1.30
in group C; p  0.46). Pretreatment bone age was significantly
negatively related to the 7-y increase in BMD50% SDS and
BMD25% SDS (0.200, p 0.001, and 0.238, p
0.001, respectively). Neither the presence of spontaneous pu-
berty or the use of estrogens, nor the 7-y increase in height
SDS were significantly related with the yearly increase in
BMD50% SDS and BMD25% SDS during 7 y of GH treatment.
A total of 11 of 65 girls (three in group A, six in group B,
and two in group C) had experienced a fracture during the
study period: humerus (n 1), wrist (n 6), hand (n 1), leg
(n  1), and foot (n  2). The annual incidence rate for
fractures of girls with TS was comparable with the published
annual incidence of a reference population of healthy girls20
y of age [25 in 1000 (95% confidence interval, 13 in 1000 to 44
in 1000) in the study group versus 19 in 1000 patient years in
the reference population] (23). The mean (SE) SDS of
BMD50% and BMD25% obtained on the visit close to the
moment of fracture were 0.44 (0.23) and 0.74 (0.23), respec-
tively. None of the values were below 2 SD.
DISCUSSION
In this longitudinal study, volumetric BMD was assessed in
relatively young girls with TS before and during long-term
treatment with supraphysiological GH dosages. We show that
most untreated young girls with TS have a normal volumetric
BMD of the bone consisting predominantly of cortical bone, as
well as that of bone consisting predominantly of trabecular
bone compared with healthy girls. Our pretreatment data are in
line with the data of Ross et al. (5), who found normal BMD
values of the wrist (predominantly cortical bone) and the spine
Figure 1. The individual BMD50% values (left panel) and the BMD25% values (right panel) before (filled squares, n  65) and after (open squares, n  39)
7 y of GH treatment. The statistical analysis is performed using all data of the total group of 65 girls by RMANOVA. The mean and range (2 SD to 2 SD)
of the reference data for healthy girls are indicated.
Table 2. The number of girls per year of whom SD scores were available and the mean (SE) BMD SD scores of the available data per
year
Years of GH treatment
0 1 2 3 4 5 6 7
BMD50% SD score
Group A 0.66 (0.40) 0.09 (0.31) 0.52 (0.21) 0.59 (0.20) 0.93 (0.19) 0.50 (0.21) 0.84 (0.25) 0.91 (0.27)
(n  11) (n  13) (n  17) (n  20) (n  21) (n  19) (n  15) (n  16)
Group B 0.15 (0.36) 0.12 (0.26) 0.28 (0.23) 0.31 (0.16) 0.28 (0.20) 0.34 (0.25) 0.41 (0.23) 0.79 (0.19)
(n  13) (n  16) (n  17) (n  20) (n  21) (n  15) (n  13) (n  11)
Group C 0.74 (0.35) 0.25 (0.21) 0.47 (0.19) 0.49 (0.19) 0.84 (0.18) 0.87 (0.19) 0.65 (0.26) 0.90 (0.32)
(n  11) (n  13) (n  18) (n  20) (n  21) (n  14) (n  12) (n  12)
BMD25% SD score
Group A 0.41 (0.14) 0.47 (0.22) 1.02 (0.17) 0.95 (0.14) 1.23 (0.22) 0.59 (0.25) 1.01 (0.23) 1.25 (0.23)
(n  11) (n  13) (n  17) (n  20) (n  21) (n  19) (n  15) (n  16)
Group B 0.43 (0.23) 0.27 (0.22) 0.49 (0.18) 0.43 (0.14) 0.45 (0.18) 0.38 (0.25) 0.34 (0.27) 0.76 (0.28)
(n  13) (n  16) (n  17) (n  20) (n  21) (n  15) (n  13) (n  11)
Group C 0.03 (0.24) 0.44 (0.23) 0.76 (0.24) 0.65 (0.24) 0.93 (0.21) 0.91 (0.22) 0.56 (0.29) 0.72 (0.15)
(n  11) (n  13) (n  18) (n  20) (n  21) (n  14) (n  12) (n  11)
All available data of the 65 girls were used in the repeated measurement analysis model to calculate the change in BMD SD score during the 7 y of GH
treatment.
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(predominantly trabecular bone) assessed by single-photon
absorptiometry and dual-photon absorptiometry, respectively,
after adjustment for height age in girls with TS with an age
between 4 and 13 y. Thus, although skeletal abnormalities
suggest an intrinsic bone defect in girls with TS (9, 10), this
defect does not negatively influence BMD during childhood. In
addition, the estrogen deficiency during childhood being
present in most of the girls does not result in a low BMD
during childhood.
During 7 y of GH treatment, BMD SDS showed a signifi-
cantly increment to values significantly higher than zero. The
pretreatment bone age was significantly negatively related to
the increment in BMD SDS: the younger the child at baseline,
the better the 7-y increase in BMD SDS. We found no signif-
icant influence of spontaneous puberty, the use of low-dose
estrogens, or the increase in height SDS on the increment in
BMD SDS during 7 y of GH treatment. As in most GH trials
in TS, no control group of untreated girls with TS was included
in our study. Consequently, it is unknown whether the girls
would have attained comparable BMD values after 7 y if they
had not received GH treatment. GH has both direct and indirect
actions on bone. In animal models, GH stimulates osteoblast
number and function and the production of various bone matrix
factors (24). Paracrine activity of osteoblasts stimulates oste-
oclasts. Bone formation is enhanced preferentially to bone
resorption during GH administration (24). In GH-deficient
children, an increment in volumetric BMD was found after
long-term GH treatment (25, 26). Lanes et al. (27) assessed the
BMD by DXA in prepubertal girls with TS while on GH
treatment. The BMD of the lumbar spine (predominantly tra-
becular bone) was significant greater than in the control group
of healthy children paired for bone age and height, whereas no
differences in the BMD of the total body or femoral neck
(predominantly cortical bone) were found. Neely et al. (28)
reported BMD in prepubertal and pubertal girls with TS re-
ceiving GH treatment. Both lumbar and total body BMD and
bone mineral apparent density were greater in the group with
TS than in the control subjects matched for height. Shaw et al.
(29) described the BMD of the lumbar spine measured by DXA
in 14 girls with TS who had received GH and/or estradiol or no
treatment. These girls had a normal baseline BMD, but a
reduction in their BMD SDS after 2.5 y. No advantage was
found for any form of treatment in optimizing bone mineral-
ization. In the present study, we showed that the BMD of the
bone consisting predominantly of cortical bone, as well as that
of bone consisting predominantly of trabecular bone, increased
significantly during GH treatment. Because we do not know
the development of the BMD in untreated girls with TS, we
cannot prove that the increment in BMD during treatment is the
result of GH administration. However, the higher increment in
BMD SDS of the “cortical” bone in the girls receiving the
highest GH dose compared with the other two GH dosage
groups suggests that GH treatment may have a positive effect
on BMD.
Most girls with TS are estrogen-deficient during both their
pre- and postpubertal years. It is well known that estrogens are
required to attain a normal peak bone mass, which is a major
determinant of osteoporosis later in life. Davies et al. (7)
described the BMD in women with TS and in women with
other causes of primary amenorrhoea, using estrogen replace-
ment therapy in most of the cases. Both groups had severe
osteopenia compared with healthy controls, after correction for
weight and height. Because estrogen therapy was not started in
most of these women until young adulthood, it was concluded
that estrogen therapy should be instituted from an early age in
patients with TS. In the present study, we show that low-dose
estrogens in the fifth, sixth, and/or seventh year of GH treat-
ment in 35 of the 64 girls did not significantly attribute to the
increment in BMD SDS. A previous study on the effects of
increasing estrogen dosages up to adult levels after discontin-
uation of GH treatment showed, however, that prolonged
treatment with higher estrogen dosages than used in the present
study does have a beneficial effect on BMD in girls with TS
resulting in a normal adult BMD (30).
Only Ross et al. (5) reported a higher incidence of wrist
fractures compared with healthy girls in a group of untreated
prepubertal girls with TS with normal BMD. In the present
study, we showed that the annual incidence rate for fractures in
the girls with TS was comparable with that for a reference
population of healthy girls. More data are available about the
incidence of osteoporotic fractures in adults with TS. Davies et
al. (7) showed a significantly higher frequency of fractures in
women with TS than in a control group. Half of the fractures
occurred at typical osteoporotic sites (wrist, spine, femoral
neck). In addition, on the basis of data from a large database of
women with TS, Gravholt et al. (6) reported an increased
incidence of osteoporosis and fractures. Although insufficient
estrogen therapy has a role in osteopenia, other factors, such as
an intrinsic bone defect, may contribute to the increased risk of
fractures in later life (9, 10).
In conclusion, most untreated young girls with TS have a
normal volumetric BMD compared with healthy girls. During
7 y of GH treatment with 4, 6, or 8 IU/m2/d, the BMD SDS
increased significantly. Only for the bone consisting predom-
inantly of cortical bone was the 7-y increment in BMD signif-
icantly higher in the girls receiving GH doses up to 8 IU/m2/d.
Spontaneous puberty or low-dose estrogen therapy in the last
3 y of the 7-y study period in girls 12 y of age did not
significantly contribute to the increase in BMD. Because these
girls have not attained their peak bone mass yet, follow-up into
adulthood is required.
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